FIELD: oncology.
SUBSTANCE: invention relates to a compound with formula 1 or a pharmaceutically acceptable salt thereof, as well as a pharmaceutical composition for the treatment or prevention of lung cancer expressing a mutation in the epidermal growth factor receptor. In general formula 1, A, B, D, E and G are combinations of A=N, B=C, D=C, E=C and G=N or combinations of A=N, B=C, D=N, E =C and G=C, W is oxygen or NH, X and Y are each independently CH, oxygen or nitrogen, Z1 and Z2 are each independently C1-C 4 alkyl or each independently consists of a carbon atom and linked to each other to form a 6-membered heterocyclic ring containing 1 N together with X and Y provided that when X is oxygen then Z1 is absent and when Y is oxygen then Z2 is absent, R1 is C1-C4 alkyl, R2 is hydrogen or C1-C4 alkyl, R3 and R4 are each independently hydrogen, halogen, OH, OMe, OEt, CN, CF3, C1-C4-alkyl or linked to each other with the formation of a 5- or 6-membered heteroaryl ring, which contains at least one heteroatom selected from the group consisting of N, O and S, R5 represents hydrogen, halogen, OH, OMe, OEt, CN, CF3 or C1-C4-alkyl, R6 and R7 are each independently hydrogen, halogen, OH, OMe, OEt, CN, CF3, COOH, COO-C1-C4-alkyl, COO-C1-5-cycloalkyl, C1 -C4 -alkyl or connected to each other to form a 5- or 6-membered heteroaryl ring, R8 is hydrogen, halogen, OH, OMe, OEt, CN, CF3 or C1-C4-alkyl, R9 represents -C(O)-CH=CH2 or C1-C4-alkyl, and R10 is absent, represents hydrogen, halogen, C1-C4-alkyl, OH, OMe, OEt, CN, CF3, NMe2, piperazine substituted with C1-C3 alkyl piperazine, morpholine or morpholine substituted with C1-C3 alkyl.
EFFECT: providing compounds suitable for the treatment of lung cancer expressing a mutation in the epidermal growth factor receptor.
5 cl, 1 tbl, 1 ex
1
| Title | Year | Author | Number |
|---|---|---|---|
| NEW PYRIMIDINE DERIVATIVE WITH AN EFFECT OF INHIBITING GROWTH OF CANCER CELLS AND PHARMACEUTICAL COMPOSITION CONTAINING IT | 2018 |
|
RU2744168C1 |
| PYRIDOPYRIMIDINONE DERIVATIVES AND USE THEREOF AS AROMATIC HYDROCARBON RECEPTOR MODULATORS | 2021 |
|
RU2818954C1 |
| 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE OF SAID COMPOUND | 2015 |
|
RU2704129C2 |
| INHIBITOR OF EGFR AND PRODUCTION AND USE THEREOF | 2015 |
|
RU2702631C2 |
| ANILINE PYRIMIDINE DERIVATIVES AND USE THEREOF | 2016 |
|
RU2734849C2 |
| COMPOUNDS AND A COMPOSITION FOR MODULATING THE KINASE ACTIVITY OF EGFR MUTANTS | 2015 |
|
RU2727700C2 |
| NEW PYRIMIDINE DERIVATIVE SUBSTITUTED WITH DEUTERIUM AND PHARMACEUTICAL COMPOSITION CONTAINING IT | 2020 |
|
RU2811770C1 |
| DERIVATIVES OF 2,4-SUBSTITUTED PHENYLENE-1,5-DIAMINE AND THEIR USES, PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS OBTAINED FROM THEM | 2015 |
|
RU2649001C1 |
| INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR | 2013 |
|
RU2679130C2 |
| PYRROLOTRIAZINE DERIVATIVES AS KINASE INHIBITOR | 2018 |
|
RU2726632C1 |
